Federal regulators have warned a Waco company that its human amniotic products are “unlicensed” and “unapproved,” and that ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) ("NurExone" or the "Company") is pleased to announce the formation of a U.S.-based ...

Kennedy’s potential ascent as HHS secretary brings promise for backers of alternative-health approaches, while skeptics say ...

North Carolina achieved a record-breaking year for life sciences investments in 2024. Twenty-five companies announced ...

Exo-Top was established under the jurisdiction of the State of Nevada. Basing Exo-Top in the U.S. offers key advantages, including proximity to strategic partners, access to a robust biopharma ...

These initiatives represent a way to accelerate access to treatments that have historically faced longer regulatory pathways.

In one such case, the FDA in November cautioned Frontier Biologics of Waco, Texas, that it was manufacturing unapproved new drugs. Company executives told The Post they disagree with the agency ...

In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio's Intelligent Hundred-Trillion Molecule Library (AI-STAL) has ...